Eric Pauwels sold $1.6M of PTCT
CHIEF BUSINESS OFFICER at PTC THERAPEUTICS, INC.. 20,508 shares at an average of $77.26, traded Dec 19, 2025, filed Dec 23, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 29% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.0%, 3m -16.9%, 6m +5.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001323212-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | MOption exercise Common Stock10b5-1 | +138 | $66.49 | $9,176 | 70,511 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -37 | $75.66 | $2,799 | 70,474 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -42 | $77.26 | $3,245 | 70,432 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -59 | $78.01 | $4,603 | 70,373 | Dec 23, 2025 |
| Dec 19, 2025 | MOption exercise Common Stock10b5-1 | +565 | $18.01 | $10k | 70,938 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -193 | $75.45 | $15k | 70,745 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -313 | $77.73 | $24k | 70,432 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -59 | $78.43 | $4,627 | 70,373 | Dec 23, 2025 |
| Dec 19, 2025 | MOption exercise Common Stock10b5-1 | +19,805 | $66.49 | $1.3M | 90,178 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $75.77 | $114k | 88,678 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -4,537 | $76.33 | $346k | 84,141 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -10,548 | $77.55 | $818k | 73,593 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -3,220 | $78.33 | $252k | 70,373 | Dec 23, 2025 |
| Dec 19, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -138 | $0.00 | $0 | 19,805 | Dec 23, 2025 |
| Dec 19, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -565 | $0.00 | $0 | 17,566 | Dec 23, 2025 |
| Dec 19, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -19,805 | $0.00 | $0 | 0 | Dec 23, 2025 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $12k 192 shares | -0% | |
| Pro nowfree Oct 16, 2026 | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.8M 25,000 shares | -2% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.8M 25,000 shares | -2% | |
| 7Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $204k 2,813 shares | -3% | |
| 34Weak | PTC THERAPEUTICS, INC. | Matthew B. Klein CHIEF EXECUTIVE OFFICER | $706k 10,292 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.